title: Synthetic oleanane triterpenoids: magic bullets or not?
abstract: A recent clinical trial in patients with chronic kidney disease (CKD) and diabetic nephropathy demonstrated that bardoxolone methyl (CDDO-ME) increases estimated glomerular filtration rate (eGFR) by an unknown mechanism. The paper by Ding et al. suggests that short-term administration of a CDDO-ME analog increases GFR by increasing glomerular surface area. However, changes in other renal hemodynamic parameters cannot be excluded. Vigorous testing of CDDO-ME and highly purified analogs is warranted to determine their physiology, pharmacology, and efficacy and to exclude serious side effects.
authors: Nephrology Division, University of Texas Health Sciences Center San Antonio, Texas, USA. Abboud@uthscsa.edu
authors: Hanna E
authors: HE
authors: Abboud
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D048430:Cell Shape / Q000187:drug effects*; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D008297:Male; D050527:Mesangial Cells / Q000187:drug effects*; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: C518860:2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide; D000804:Angiotensin II; D009828:Oleanolic Acid